Clinical Trials

Showing 121 - 140 of 507 trials
Title Investigatorsort icon Disease(s)
A Phase I Study of EGF816 in Patients with Lung Cancer Containing the EGFR T790M Mutation
[Protocol 14-112]
Riely, Gregory
  • Lung Cancer, Non-Small Cell
A Phase I/II Study of the ALK Inhibitor CH5424802 in Patients with ALK-Rearranged Non-Small Cell Lung Cancer
[Protocol 12-113]
Riely, Gregory
  • Lung Cancer, Non-Small Cell
    • Lung Adenocarcinoma
A Phase I/II Study of Crizotinib and Ganetespib (STA-9090) in ALK-Positive Lung Cancers
[Protocol 12-015]
Riely, Gregory
  • Lung Cancer
  • Lung Cancer, Non-Small Cell
    • Lung Adenocarcinoma
A Phase II Study of Temozolomide Alone and with Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors
[Protocol 13-194]
Reidy-Lagunes, Diane
  • Hepatobiliary
    • Pancreatic Cancer
  • Upper Gastrointestinal
    • Neuroendocrine
    • Pancreatic Cancer
A Phase II Study of MLN0128 in Men with Castration-Resistant Prostate Cancer
[Protocol 13-143]
Rathkopf, Dana
  • Prostate Cancer
    • Metastatic Disease after Hormone-Reducing Therapy
A Phase III Study of ARN-509 versus Placebo in Men with Non-Metastatic Castration-Resistant Prostate Cancer
[Protocol 13-243]
Rathkopf, Dana
  • Prostate Cancer
    • Rising PSA After Primary Therapy
A Study of Degarelix Before Prostatectomy in Patients with Intermediate- to High-Risk Prostate Cancer
[Protocol 11-182]
Rathkopf, Dana
  • Prostate Cancer
    • Localized Disease
A Phase Ib Study of ARN-509 plus Everolimus in Men with Progressive Metastatic Castration-Resistant Prostate Cancer After Abiraterone Therapy
[Protocol 13-025]
Rathkopf, Dana
  • Prostate Cancer
    • Metastatic Disease after Hormone-Reducing Therapy
A Phase IA/B Study of CC-115 in Castration-Resistant Prostate Cancer
[Protocol 12-080]
Rathkopf, Dana
  • Prostate Cancer
    • Metastatic Disease after Hormone-Reducing Therapy
Development and Validation of a New Patient-Reported Outcome Instrument on the Impact of Altered Facial Appearance Following Oncologic Head and Neck Resection and Reconstruction
[Protocol 07-098]
Pusic, Andrea
  • Head & Neck Cancer
  • Survivorship
Mastectomy Reconstruction Outcomes Consortium (MROC) Study
[Protocol 11-175]
Pusic, Andrea
  • Breast Cancer
  • Survivorship
Expanded Access of Prochymal Infusion for the Treatment of Pediatric Patients with Acute Refractory GVHD
[Protocol 09-072]
Prockop, Susan
  • Blood and Marrow Transplantation
    • Transplantation
A Study Analyzing Patients Treated for Wiskott-Aldrich Syndrome Since 1990
Newly Diagnosed & Relapsed/Refractory
[Protocol 14-066]
Prockop, Susan
  • Hematology
    • Hematologic Disorders
Expanded Access to MK-3475 for Patients with Metastatic Melanoma with Few to No Treatment Options
[Protocol 14-093]
Postow, Michael
  • Melanoma
A Phase II Study of LEE011 plus LGX818 in Patients with BRAF-Mutant Melanoma
[Protocol 13-097]
Postow, Michael
  • Melanoma
A Phase II Study of LEE011 plus MEK162 in Patients with NRAS-Mutant Melanoma
[Protocol 13-102]
Postow, Michael
  • Melanoma
A Phase Ib Study of AEB071 and MEK162 in Patients with Advanced Uveal Melanoma
[Protocol 13-172]
Postow, Michael
  • Melanoma
    • Melanoma of the Eye
A Phase I Study of the NY-ESO-1 Vaccine plus Ipilimumab in Patients with Inoperable or Metastatic Melanoma
[Protocol 12-253]
Postow, Michael
  • Melanoma
A Phase II Study of Dacarbazine with and without Selumetinib to Treat Metastatic Uveal Melanoma
[Protocol 14-033]
Postow, Michael
  • Melanoma
    • Melanoma of the Eye
A Phase III Study of MEK162 versus Dacarbazine in Patients with Inoperable or Metastatic Melanomas with NRAS Q61 Mutations: The NEMO Trial
[Protocol 13-083]
Postow, Michael
  • Melanoma